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Abstract
Background: Adequate reporting of safety in publications of randomized controlled trials (RCTs) is a pre-requisite
for accurate and comprehensive profile evaluation of conventional as well as complementary and alternative
medicine (CAM) treatments. Clear and concise information on the definition, frequency, and severity of adverse
events (AEs) is necessary for assessing the benefit-harm ratio of any intervention. The objectives of this study are to
assess the quality of safety reporting in CAM RCTs; to explore the influence of different trial characteristics on the
quality of safety reporting.
Methods: Survey of safety reporting in RCTs published in 2009 across 15 widely used CAM interventions identified
from the Cochrane Collaboration’s CAM Field specialized register of trials. Primary outcome measures, the adequacy
of reporting of AEs; was defined and categorized according to the CONSORT for harms extension; the percentage of
words devoted to the reporting of safety in the entire report and in the results section.
Results: Two-hundred and five trials were included in the review. Of these, 15% (31/205) reported that no harms
were observed during the trial period. Of the remaining 174 trials reporting any safety information, only 21% (36/
174) had adequate safety reporting.
For all trials, the median percentage of words devoted to the reporting of safety in the results section was 2.6.
Moreover, 69% (n = 141) of all trials devoted a lesser or equal percentage of words to safety compared to author
affiliations. Of the predictor variables used in regression analysis, multicenter trials had more words devoted to
safety in the results section than single centre trials (P = 0.045).
Conclusions: An evaluation of safety reporting in the reports of CAM RCTs across 15 different CAM interventions
demonstrated that the reporting of harms was largely inadequate. The quality of reporting safety information in
primary reports of CAM randomized trials requires improvement.
Background
Adequate reporting of safety in primary publications of
randomized controlled trials (RCTs) is a pre-requisite
for accurate and comprehensive profile evaluation of
conventional as well as complementary and alternative
medicine (CAM) interventions. Clear and concise infor-
mation on the frequency and severity of Adverse Events
(AEs) is necessary in assessing the benefit-harm ratio
when administering any intervention. In 2007, it was
estimated that 38.3% of American adults use some form
of CAM [1]. With such high usage rates, it is essential
that the evidence is of the highest quality and that safety
information is reported in sufficient detail.
In 1998 and 2001, Ioannidis and Lau published a
study evaluating the reporting of safety data in 7 medi-
cal areas [2,3]. This evaluation concluded that the
reporting of safety data was largely inadequate. More-
over, the absolute space given to author affiliations was
often more than that given to the reporting of safety. * Correspondence: lturner@ohri.ca
1Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital
Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada
Full list of author information is available at the end of the article
Turner et al. BMC Complementary and Alternative Medicine 2011, 11:67
http://www.biomedcentral.com/1472-6882/11/67
© 2011 Turner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Ioannidis called for the replication of such an evaluation
across many fields.
While there have been recent advances in conven-
tional medicine to standardize the collection, analysis
and reporting of efficacy data in clinical trials [4], and
more recently, the reporting of safety [5], there is little
evidence regarding adequacy of reporting within CAM
trials. Referencing Ioannidis’ objectives and methods,
this study evaluates safety information across 15 CAM
interventions. Our aim was to assess the adequacy of
safety reporting in CAM trials, to gain a better under-
standing of the predictors of adequate reporting, and to
extend and assess adherence of CAM RCTs to the
CONSORT recommendations for harms extension [6].
Methods
Trial Database
We searched the Cochrane Complementary Medicine
Field (CAM Field) Specialized Register of trials [7] and
obtained citations to all CAM RCTs published in 2009
pertaining to 15 CAM intervention categories. The
inclusion of study reports was not restricted by study
sample size or language of publication. All non-full text
reports were excluded along with reports which could
be categorized by more than one intervention; had AEs
as a primary outcome; or for which full text articles
were not locally available.
Selecting Interventions
The top 5 most commonly used CAM therapies accord-
ing to the National Health Interview Survey 2007 were
the following: 1. Natural products (17.7%); 2. deep
breathing (12.7%); 3. meditation (9.4%); 4. Chiropractic
and osteopathic (8.6%); and 5. massage (8.3%)[8].
Because natural products are by far the most commonly
used CAM therapy, we focused on that CAM topic area,
however only included the top 10 most commonly used
natural products in our sample [9]. There is wide accep-
tance of minimal, if any, AEs associated with deep
breathing and meditation; hence these topics were
excluded from our study. In addition, we decided to
include acupuncture and Chinese herbal medicine CAM
topic areas despite not being among the top 10 most
commonly used CAM therapies, as both topics are of
popular interest, widely used globally [10,11] and there
is much available literature [12].
As such, 15 CAM interventions classified according to
categories developed by the Cochrane CAM field, were
chosen based on their respective impact, accessibility
and frequency of use [13]. Interventions include: acu-
puncture, massage, chiropractry, traditional Chinese her-
bal medicine and other traditional medicine, fish oil/
omega 3, glucosamine, flaxseed, ginseng, combination
herbal products, ginkgo biloba, garlic supplements,
coenzyme Q-10, echinacea and chondroitin. Acupunc-
ture was defined as a needling intervention, breaking the
skin [14], as such Moxibustion, TENS (transcutaneous
electrical nerve stimulation), laser acupuncture and acu-
pressure trials were not included.
Study selection and data extraction
Retrieved trials were screened and data extracted using
online review software, DistillerSR. Title and abstract
screening was conducted in duplicate by two of three
review authors and subsequent full text articles were
retrieved and screened independently by two of five
reviewers, any disagreements were discussed and remain-
ing conflicts were resolved by a third independent author.
Standardized data extraction forms were created to
ensure all reported data was collected from the trials
meeting inclusion criteria. All data to be collected was
determined a priori. Data extraction was completed inde-
pendently and verified by two authors by taking a 10%
random sample of trials. A discrepancy of 10% in the
number of words extracted was defined to be acceptable,
however only two trials exceeded this cut off. Only 6.5%
of all extracted data was modified. There were no amend-
ments to outcomes which were considered to threaten
the reliability of the data and as a result, no further expli-
cit verification by study was conducted.
Evaluation and Analysis
Descriptive Characteristics
Descriptive characteristics of included trials were based
on variables which could be potentially used to predict
qualitative and quantitative measures of reporting safety
data. Founded upon the variables considered by Ioanni-
dis with additions and modifications subject to the con-
text of this evaluation, descriptive characteristics
included: Total sample size; whether or not a trial was
reported as double-blind; whether or not the trial
reported significant results for efficacy; type of funding,
industry versus non-industry; longest duration to follow
up subject to CAM trials (a 6 month divide was deemed
appropriate). We recorded information to assess if more
words or more adequate reporting was given to safety
information in paediatric trials, therapeutic trials (versus
preventative) studies which were in combination with
conventional medicine (i.e. Acupuncture and Che-
motherapy) and studies which were conducted at multi-
ple centres. We also collected 2009 impact factor
information for publishing journals of included studies;
this information was collected from the journal websites.
Adequacy of Safety Reporting: Qualitative and
Quantitative Measures
Qualitative and quantitative components of AEs reporting
offer complementary information. The measures
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the selection of qualitative and quantitative measures for
this evaluation. We measured the following two qualitative
components: 1. the reporting of dropouts due to AEs and
whether the total number of dropouts were reported; and
2. Whether severity of the described AEs were reported,
such reporting was classified as adequate, partially ade-
quate, inadequate or no harms reported (Figure 1).
In order to determine the relative emphasis of safety
reporting in these CAM reports we assessed quantitative
measures, namely, the percentage of words reporting
safety in the body of the text and the percentage of
words reporting safety in the results section. The full
body of the text was defined as all words in the trial
report excluding the title, abstract, acknowledgements,
appendices and affiliations. Sentences including any
words reporting harms were not broken. Like Ioannidis,
we compared the relative reporting of safety in the body
of the text with the text given to author affiliations. We
also extracted the number of words devoted to the
reporting of safety and the total number of words in the
results section to compute the percentage of words
devoted to safety in the results section.
CONSORT for Harms
In 1996, a group of international experts published the
CONSORT Statement [15]. This reporting guideline was
updated in 2001 and more recently in 2010 [16,17]. Sev-
eral extensions to facilitate reporting of other trial
designs, such as cluster trials, and other types of data
including harms, have been developed. We applied the
CONSORT for harms extension collecting data on each
of the first seven recommendations described as part of
this evaluation (Figure 2).
Data Analysis
All descriptive characteristics are reported by CAM
area as the frequencies and percentages of trials with
the exception of sample size and 2009 journal impact
factor for which median and inter-quartile ranges are
reported. Descriptive characteristics were used as pre-
dictor variables in both least-squares multiple regres-
sions and binary logistic regressions. The qualitative
and quantitative measures of percentage of words
devoted to the reporting of safety in the results sec-
tion, and adequacy of reporting were respective depen-
dent variables. Multiple least-squares analyses for each
predictor were run adjusting for CAM area by dummy
variables. Logistic regressions of clinical AEs (no
harms reported and adequate reporting versus partially
adequate and inadequate) were also run. Similarly, all
analysis was adjusted for CAM therapy using dummy
variables. All analysis was conducted using Minitab
®
Version 16.1.1.
Adequate definition of severity required either detailed description of the severity or reference to a known scale of severity, 
with separate reporting of at least severe or life threatening events. At least 2 adverse effects have to be defined in this way, 
with numbers or rates given for each study arm. 
Partially adequate is defined as, trial reports of severity combine moderate with severe counts, or that the numbers of 
severe cases are separately specified for only 1 of many reported clinical adverse events per study arm. 
Inadequate definition of severity includes protocols reporting the total number of severe adverse events and those not 
reporting adverse effects at all. We also included a category for those studies that explicitly stated no adverse events were 
observed; in these cases no scale or description could be provided. 
‘No harms reported’; where the trial clearly reports that no adverse events were experienced. This addition was made to 
allow for studies which did not encounter any harms data and would not meet the definition of ‘adequate’ reporting. 
Figure 1 Defining qualitative parameters for adequacy of reporting.
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Search results and included trials
A total of 487 trials were identified. Of these, 166 trials
were excluded as full text articles were not available; 29
trials were excluded as they did not fall under any of
the 15 pre-defined CAM intervention categories; 87
more trials were excluded for not meeting our eligibility
criteria (e.g., protocols, non-randomized trials, secondary
publications, primary outcome AEs, incalculable word
count, non-human study). Two of the fifteen CAM
areas, echinacea and chondrotin, did not yield any trials.
The remaining 205 trials, representing 13 different
CAM areas, were included in the review (Figure 3).
Descriptive Characteristics of Included Trials
Descriptive characteristics of included trials are pre-
sented in Table 1. Of the 205 included trial reports, 48%
(n = 99) were described as double-blind. The majority
of trials (74%, n = 152) evaluated a therapeutic CAM
intervention versus a preventative intervention, and 23%
(n = 47) of interventions were a combination of CAM
and non-CAM treatments. Only five of the 13 CAM
categories (acupuncture, Chinese herbal medicine, co-
enzyme Q-10, combination herbal products and fish oil)
included a paediatric population.
Seventy six (37%) trials did not report a source of fund-
ing. Thirty three (16%) trials were funded by industry, 47
(23%) by government, 49 (24%) by academic institutions.
Eighty three (40%) trials did not report the longest dura-
tion of follow up. Only 35 (n = 17%) of trials were multi-
centered. The median 2009 journal impact factor for all
publications was 1.86 (range 0.42 to 9.81). One study,
published in JAMA, was not included in the calculation
due to a comparatively large 2009 impact factor.
Adequacy of safety reporting
Qualitative measures
Fifteen percent (31/205) of trials explicitly reported that
no AEs had been experienced during the trial. More
than half of all trials (56%, 114/205) had inadequate
reporting of safety data. Of these, 69% (79/114) had no
words dedicated to the reporting of harms anywhere in
the trial report. In 18% (36/205) of all trials the report-
ing of safety was deemed to be adequate and in 12%
(24/205) of the trials, the safety reporting was consid-
ered as partially adequate. Although treatment disconti-
nuation was reported in 79% (162/205) of trials, the
number reporting details on dropouts due to AEs was
less at 60% (124/205) (Table 2).
Quantitative measures
The median percentage of words for reporting safety in
the full body of the text was 0.94 (Q1-Q3 0.00-3.26).
The median percentage of words in the results section
devoted to the reporting of safety was 2.55 (Q1-Q3
0.00-11.07). Less than 30% (n = 60) of trials devoted an
equal or greater percentage of words for the reporting
CONSORT ITEMS: Assessment of the quality of reporting by the CONSORT for harms extension 
recommendations. 
1.  Does the title or abstract state that data on harms were collected? 
2.  Does the introduction state if there were harms reported (or not)? 
3.  Did the study authors pre-specify potential adverse events? (with attention, when relevant, to 
grading, expected vs. unexpected events. Reference standardized and validated definitions and 
description of new definitions). 
4.  Does the study clarify how harms-related information was collected? (Passive, active, mode of data 
collection, timing, attribution methods, intensity of ascertainment, and harms-related monitoring and 
stopping rules, if pertinent). 
5.  In the methods section, does the study describe plans for presenting and analyzing information on 
harms? (Including coding, handling of recurrent events, specification of timing issues, handling of 
continuous measures, and any statistical analyses). 
6.  Does the participant flow describe for each arm the participant withdrawals that are due to harms 
with the allocated treatment? 
7.  Does the study provide any specific denominator(s) for analyses on harms? 
 
Figure 2 CONSORT for Harms Data Recommendations.
Turner et al. BMC Complementary and Alternative Medicine 2011, 11:67
http://www.biomedcentral.com/1472-6882/11/67
Page 4 of 10of safety than to author affiliations (Table 3). In 141
(69%) trials more words were given to the reporting of
author affiliation information than safety information, in
4 (2%) trials the percentage of words were considered to
be the same (within 0.1%), and 60 (29%) trials gave
more space to the reporting of harms relative to the
reporting of author information.
For all trials the percentage of words for reporting
author affiliations was statistically greater than that for
reporting safety data (Wilcoxon test, p < 0.001). Two of
the thirteen CAM areas, Acupuncture and Fish Oil/
Omega 3 (P < 0.001 and P < 0.01 respectively) also
showed significant differences in the number of words
devoted to safety and affiliations, with more words given
to the reporting of author affiliations. Only 10% of trials
reported safety data in at least one table, and 5% of all
trials reported safety data in af i g u r e .S e v e n( 3 % )t r i a l s
referred to additional external resources (online or
archived) with additional safety data.
CONSORT for Harms
In general, we found a low compliance with seven
CONSORT for harms recommendations. Of these
recommendations, ‘participant flow’ yielded the highest
frequency for reporting in 30% (n = 61) of trials. The
lowest compliance (< 5% of all trials) was observed with
recommendation 2, the reporting harms information in
the introduction (Table 4).
Regression Analysis
In univariate analysis, the percentage of words devoted
to the reporting of safety in the results section increased
significantly for multicenter trials (p = 0.045), (Table 5).
In multivariable analysis, multicenter trials were retained
as a statistically significant predictor for increasing the
percentage of words in the results section of a trial irre-
spective of CAM area. It is of interest that Coenzyme
Q-10 (p = 0.017), Fish oil/Omega 3 (p = 0.018) and Flax
Seed (p = 0.043) all saw significant reductions in the
percentage of words in the results section reporting
safety. Logistic regressions did not yield any significant
increases in odds of adequate reporting of safety based
on predefined predictor variables. Although non-signifi-
cant, industry funded trials odds of adequate reporting
of harms were 2.49 times (95% CI, 0.98 to 6.32) that of
non-industry funded trials; and multicenter trials had an
odds of 1.89 (95% CI, 0.98 to 1.43) times those of single
centre trials of adequately reporting safety information.
Discussion
In general, findings of this evaluation indicate that the
safety reporting across trials of CAM interventions is
487 Total Records Retrieved 
from the Cochrane CAM Specialised Registry*
*No duplicates removed or additional studies included
487 Screened at Level One (Title and abstract only)
283 Screened at Level Two (Full Text)
205 included CAM RCTs
204 Excluded:
Reasons for exclusion:
(10) Not categorised within defined interventions
(166) Full text not locally available
(22) Did not meet acupuncture definition
(1) Non-human trial
(4) Not strict RCT
(1) Outcome adverse events
78 Excluded:
Primary Reasons for exclusion:
(19) Not categorised within defined interventions
(18) Did not meet acupuncture definition
(30) Protocols, secondary analysis or not full RCT
(5) Trials of more than one defined intervention
(4) Outcome is adverse event
(2) Inaccessible word count
Figure 3 Study Flow Diagram.
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percentage of words devoted to the reporting of safety
was equal to or less than that devoted to author affilia-
tions. Adequate reporting of AEs was only observed in
18% of trials, with a further 9% of trials reporting that
no harms were observed. Thirty-nine percent of trials
gave no mention whatsoever to potential AEs. The
regression models showed that the percentage of words
devoted to the reporting of safety was significantly
greater for the reports of multicenter trials compared to
the reports of single centered trials; but otherwise none
of the considered predictor variables were significant in
modelling the percentage of words in the results section
or the adequacy of reporting.
Consistent with the somewhat acceptable reporting of
dropouts due to AEs, the assessment of adherence to
the CONSORT for harms extension demonstrates that
participant flow diagrams are the most successfully
reported recommendation; however, this is under 30%
o ft r i a l s .N o t a b l y ,p e r h a p s ,o n l yj u s to v e r2 0 %o ft r i a l s
discuss AEs in the abstract (Recommendation 1). Similar
to the adequacy of reporting of safety outcome, the
compliance of trials to recommendations of the CON-
SORT extension is weak.
These main findings are somewhat consistent with
Ioannidis’ evaluation of seven medical areas from a dec-
ade ago. The percentage of trials adequately reporting
safety information in CAM trials was lower (18% of the
Table 1 Characteristics of included CAM RCTs
Intervention Sample
Size
Median
(Q1-Q3),
Total
Double-
blind
No. (%)
Significant
results for
efficacy
No. (%)
Industry
funded
No. (%)
Longest
duration to
follow up ≥
6 m, No. (%)
Paediatric
population
No. (%)
Therapeutic
studies No.
(%)
Combined
Studies
No. (%)
Multicenter
trials No.
(%)
Journal
IF > 5,
No. (%)
Acupuncture,
n=7 5
60 (32-102)
8,717
16 (21) 58 (77) 5 (7) 9 (12) 4 (5) 71 (95) 23 (31) 11 (15) 9 (12)
Chinese
herbal
Medicine, n =
46
71 (48-98)
6,170
20 (43) 36 (78) 3 (6.5) 6 (13) 2 (4) 32 (70) 12 (26) 11 (24) 1 (2)
Chiropractic,
n=6
32 (28-47)
402
1 (17) 4 (67) 1 (17) 1 (17) - 5 (83) 2 (33) 1 (17) -
Coenzyme Q-
10, n = 8
56 (34-166)
789
8 (100) 6 (75) 2 (25) 4 (50) 2 (25) 5 (63) - 1 (13) 2 (25)
Combination
herbal
products, n =
11
85 (52-97)
882
9 (82) 6 (55) 6 (55) 2 (18) 1 (9) 9 (82) 1 (9) 3 (27) -
Fish oil/
Omega 3, n =
29
64 (33-105)
2,671
25 (86) 14 (48) 7 (24) 10 (34) 4 (14) 14 (48) 6 (21) 3 (10) 2 (7)
Flax Seed, n
=6
48 (38-68)
321
4 (67) 4 (67) 1 (17) 1 (17) - 2 (33) - - -
Garlic
supplements,
n=2
542 (303-
780) 1,083
2 (100) 2 (100) 1 (50) 2 (100) - - 1 (50) - -
Gingko
Biloba, n = 4
80 (56-835)
3,243
2 (50) 2 (50) 1 (25) 1 (25) - 3 (75) - 1 (25) 1 (25)
Ginseng, n =
6
62 (30-85)
394
5 (83) 2 (33) 3 (50) 1 (17) - 2 (33) 1 (17) - 2 (33)
Glucosamine,
n=3
22 (19-122)
260
1 (33) 2 (67) - 2 (67) - 3 (100) - 1 (33) -
Massage, n =
1
- 35 1 (100) 1 (100) - - - - - - -
Traditional
medicine, n =
8
66 (48-108)
643
5 (63) 7 (88) 2 (25) - - 6 (75) 1 (13) 3 (38) -
TOTAL, (n =
205)
63 (36-100)
25,610
99 (48) 144 (70) 33 (16) 39 (19) 13 (6) 152 (74) 47 (23) 35 (17) 17 (8)
’-’ Denotes zero trials
’NR’ Not reported
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Clinical Adverse Events, No. (%) Discontinuations
Intervention Adequate Partially
adequate
Inadequate No harms
reported
Total
reported
Due to
adverse
events
Reporting adverse events when
reporting discontinuations
Acupuncture, n = 74 8 (11) 12 (16) 46 (61) 9 (12) 57 (76) 45 (60) 45/57
Chinese herbal
Medicine, n = 46
10 (22) 5 (11) 23 (50) 8 (17) 32 (70) 31 (67) 31/32
Chiropractic, n = 6 2 (33) 1 (17) 2 (33) 1 (17) 5 (83) 5 (83) 5/5
Coenzyme Q-10, n = 8 1 (13) - 4 (50) 3 (38) 7 (88) 4 (50) 4/7
Combination herbal
products, n = 11
3 (27) - 6 (55) 2 (18) 9 (82) 8 (73) 8/9
Fish oil/Omega 3, n =
29
3 (10) 3 (10) 19 (66) 4 (14) 27 (93) 15 (52) 15/27
Flax Seed, n = 6 2 (33) - 4 (67) - 4 (67) 3 (50) 3/4
Garlic supplements, n
=2
- - 2 (100) - 2 (100) - 0/2
Gingko Biloba, n = 4 2 (50) - - 2 (50) 4 (100) 3 (75) 3/4
Ginseng, n = 6 2 (33) - 4 (67) - 6 (100) 5 (83) 5/6
Glucosamine, n = 3 - - 2 (67) 1 (33) 2 (67) 1 (33) 1/2
Massage, n = 1 - - 1 (100) - - - -
Traditional medicine, n
=8
3 (38) 3 (38) 1 (13) 1 (13) 7 (88) 4 (50) 4/7
Total (n = 205) 36 (18) 24 (12) 114 (56) 31 (15) 162 (79) 124 (60) 124/162
Table 3 Safety of Reporting: Quantitative measures
Percentage of words for safety
reporting
Relative emphasis on safety
reporting, No. (%)
Other sources of safety data, No. (%)
Intervention Body of the text,
median (Q1-Q3)
Results section,
median (Q1-Q3)
Safety <
affiliations
Safety =
affiliations
Safety >
affiliations
≥ 1 Table for
safety data
≥ 1 Figure for
safety data
Additional
resources
Acupuncture, n =
75
0.7 (0.0-2.0) 1.2 (0.0-9.0) 56 (75) 1 (1) 18 (24) 7 (9) 3 (4) 2 (3)
Chinese herbal
Medicine, n = 46
1.5 (0.0-5.1) 7.1 (0.0-15.7) 27 (59) 1 (2) 18 (39) 6 (13) - -
Chiropractic, n = 6 2.0 (0.1-3.7) 1.8 (0.0-15.3) 3 (50) - 3 (50) 1 (17) 1 (17) -
Coenzyme Q-10, n
=8
1.2 (0.0-3.1) 1.9 (0.0-5.1) 6 (75) - 2 (25) 1 (13) 1 (13) -
Combination herbal
products, n = 11
2.7 (1.0-4.5) 6.6 (0.5-13.3) 5 (45) 1 (9) 5 (45) 2 (18) 2 (18) 1 (9)
Fish oil/Omega 3, n
=2 9
0.0 (0.0-1.8) 0.0 (0.0-6.9) 21 (72) 1 (3) 7 (24) 1 (3) 3 (10) 1 (3)
Flax Seed, n = 6 0.0 (0.0-1.4) 0.0 (0.0-6.0) 5 (83) - 1 (17) - - -
Garlic supplements,
n=2
0.0 (0.0-0.0) 0.0 (0.0-0.0) 2 (100) - - - - 2 (100)
Gingko Biloba, n =
4
1.6 (1.5-1.9) 9.0 (7.4-11.7) 4 (100) - - - - 1 (25)
Ginseng, n = 6 0.5 (0.0-2.1) 2.0 (0.0-0.6) 5 (83) - 1 (17) 1 (17) - -
Glucosamine, n = 3 0.0 (0.0-2.4) 0.0 (0.0-3.5) 2 (67) - 1 (33) - - -
Massage, n = 1 - - 1 (100) - - - - -
Traditional
medicine, n = 8
3.6 (1.1-8.4) 9.1 (3.3-21.6) 4 (50) - 4 (50) 2 (25) - -
TOTAL (n = 205) 0.9 (0.0-3.3) 2.6 (0.0-11.1) 141 (69) 4 (2) 60 (29) 21 (10) 10 (5) 7 (34)
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harms, versus 39%). Our finding that a larger percentage
of words were devoted to author affiliations compared
to AEs mirrors Ioannidis’ finding that more publication
area is devoted to author affiliations than to AEs. The
overall conclusions of both evaluations are consistent in
that the percentage of trials reporting harms and the
adequacy by which they are reported is largely inade-
quate irrespective of defined predictors.
Inadequate reporting of harms also has consequences
for systematic reviewers. The synthesis of harms from
individual trials will be seriously compromised by inade-
quate reporting. The net effect is to negate the altruistic
volunteerism of trial participants; there are important
ethical and moral reasons to improve the quality of
reporting of all research [18].
We would like to note some limitations to our evalua-
tion. This is a sample across both physical interventions
and natural products, therefore we may be assessing
interventions for which AEs rarely occur [19,20] (or
rarely in comparison to drug interventions), or by which
symptoms of overdose or usage are very minor and
would not require medical attention. As such authors
may not have considered reporting safety information.
This by no means justifies the lack of adequacy of
reporting of safety for these trials. If it is deemed by the
trialist that no such AEs could occur independently or
by interaction with other medications [21,22], this
should be sufficiently described in the trial report.
Due to limited resources, only locally available trials
were included. This excluded a large number of trials
reported in languages other than English. However,
Table 5 Regression Analysis
Increase in percentage of words devoted to the reporting of
safety in the results section
Ŧ
Adequacy of reporting
Predictors Least-square regressions (Adjusted
¥) Effect Size (95% CI) Logistic regressions (Adjusted)
OR (95% CI)
Sample Size (per 10 unit increase) 0.02 (-0.04-0.07) 1.00 (1.00-1.00)
Double Blind 2.86 (-1.04-6.76) 1.05 (0.47-2.31)
Significant results for efficacy -1.93 (-5.36-1.49) 1.18 (0.03-1.40)
Industry Funded 0.27 (-4.04-4.58) 2.49 (0.98-6.32)
Longest duration to follow-up, ≥ 6
m
-0.07 (-4.04-3.91) 0.99 (0.42-2.33)
Paediatric population -4.50 (-11.07-2.07) 0.56 (0.11-2.90)
Therapeutic studies 3.21 (-0.84-7.26) 1.81 (0.73-4.48)
Combined studies -0.32 (-4.03-3.39) 0.79 (0.34-1.81)
Multicentre 4.02 (0.12-7.92)* 1.89 (0.84-4.27)
2009 Journal Impact Factor (per 10
unit increase)
1.05 (-6.01-8.18) 1.19 (0.98-1.43)
*Statistically significant, p = 0.045,
¥All regressions adjusted for CAM intervention,
ŦMultiple least-squares regressions for each predictor detailed. Adjusted forced
entry (p < 0.1) and stepwise elimination and entry models retain multicenter (p = 0.03) and therapeutic studies (0.02).
Table 4 Reporting of Safety in accordance with CONSORT for Harms Recommendations
CONSORT for Harms Recommendation, No. (%)
Intervention 1 2 3 4 5 6 7
Acupuncture, n = 74 13 (17) 2 (3) 5 (7) 9 (12) 6 (8) 29 (39) 16 (21)
Chinese herbal Medicine, n = 46 16 (35) 3 (7) 7 (15) 11 (24) 5 (11) 9 (20) 10 (22)
Chiropractic, n = 6 2 (33) 1 (17) - - 1 (17) 2 (33) 2 (33)
Coenzyme Q-10, n = 8 1 (13) - 1 (13) 1 (13) - 3 (38) 1 (13)
Combination herbal products, n = 11 5 (45) 1 (9) - 2 (18) - 4 (36) 2 (18)
Fish oil/Omega 3, n = 29 1 (3) 1 (3) 1 (3) 4 (14) - 8 (28) 2 (7)
Gingko Biloba, n = 4 - - - 1 (25) - 1 (50) -
Ginseng, n = 6 1 (17) - - 1 (17) - 2 (33) 2 (33)
Glucosamine, n = 3 1 (33) - - 1(33) - - -
Traditional medicine, n = 8 4 (50) 1 (13) - 3 (38) - 1 (13) 2 (25)
TOTAL (n = 205) 43 (21) 9 (4) 13 (6) 34 (17) 12 (6) 61 (30) 37 (18)
Please Note: None of the trials of flax seed, garlic supplements or massage adhered to any of the CONSORT recommendations
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ing of adequacy across all CAM areas, it is unlikely that
the exclusion of these trials would greatly affect our
results. We have drawn comparison between proportion
of words given to author affiliation and safety of report-
ing. Our results suggested that 69% of trials devoted
more words to author affiliations than reporting of
safety, and 29% devoted more words to safety than
affiliation. This discrepancy may be somewhat con-
founded by a number of external influences such as edi-
torial policy, number of investigators involved with a
study and for the trials which report no harms. We feel
however, that although the difference may not be as
large as reported, this does not negate the finding that
more trials devoted more space to author affiliations
than to the reporting of safety.
We would also like to note that not all trials were
included in the regression analysis (n = 172). Trials with
missing data on duration to follow up and trials pub-
lished in new journals without 2009 impact factors were
omitted. The fit of all regression models was poor. This
would suggest that either there are other variables asso-
ciated with the quality of reporting of safety data which
we did not consider, or these characteristics can by no
means predict the quality of reporting, and that ulti-
mately, the reporting of AEs is independently subject to
the study author.
It could be hypothesised that there would be an asso-
ciation between journal endorsement of the CONSORT
statement and trial adherence to the CONSORT for
harms extension. Hopewell et al. report in 2008 the
adherence to the CONSORT for harms statement is
mentioned in only 3 of 165 high impact medical jour-
nals [23]. It is likely that this lack of endorsement is
consistent within our sample; we did not investigate this
association in this evaluation as the proportion of adher-
ing journals would be sparse.
This study provides strong evidence, including many
trials across many well established CAM interventions,
that the reporting of safety data is inadequate. While
there have been ongoing strides in conventional medi-
cine to standardizing the collection, analysis and report-
ing of efficacy data in clinical trials [4], and more
recently, the reporting of safety [5]; the Cochrane CAM
Field has found no other evidence regarding the ade-
quacy of such reporting within CAM trials. Hence, this
study is the likely the first to provide such information.
Given the increasing use of CAM, it is necessary to
improve such reporting to enable accurate and objective
marketing and use of such treatments or products.
Although large robust trials have a lot of information to
report, it is not acceptable for the reporting of safety to
be overlooked. Sufficient guidance must be provided to
authors to ensure that the safety data is comprehensive
and accessible to readers even when there have been no
observed AEs.
The CONSORT for harms extension is a valuable
resource for improving the quality of reporting of harms
in conventional medicine trials. However, it is clear that
there is a need for the use of such guidance to become
standard procedure for authors and editors when pre-
senting findings for all trials. Few journals explicitly
endorse CONSORT for harms or other reporting guide-
lines. Parenthetically, there is growing evidence that use
of reporting guidelines is associated with improved qual-
ity of reporting [24-26]. Plint and colleagues reported a
systematic review of eight trials evaluating the use of the
CONSORT checklist and found that its use was asso-
ciated with improved quality of reporting. A recent
update of this review [27] now includes 49 studies
examining almost 9000 trials provides strong stronger
support for the association between use of the CON-
SORT checklist and improved reporting.
Conclusions
An evaluation of safety reporting in the reports of CAM
RCTs across 15 different CAM interventions demon-
strated that the reporting of harms was largely inade-
quate. The quality of reporting safety information in
primary reports of CAM randomized trials requires
improvement. We hope that these data will impress
journal editors who, in turn will now endorse reporting
guidelines as an important way to improve the quality
of reporting harms.
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